This study marks Thailand’s first application of Distributional Cost-Effectiveness Analysis (DCEA), demonstrating that the concept of “equity” can be incorporated into economic evaluation. The analysis examines dialysis options, namely peritoneal dialysis (PD) and hemodialysis (HD), for patients

Recognizing the benefits of economic evaluations as a tool to inform public health policy, the Bill and Melinda Gates Foundation (BMGF) in collaboration with the Tufts Medical Center has endeavored to aid in creating the tools, mechanisms, and frameworks to facilitate the generation of research, assessments, and evaluations globally. While the conc

The study suggests that the price of patented medicine in Thailand should be controlled based on equity pricing and outcome pricing. Equity pricing can be estimated from the international reference price and outcome pricing can be evaluated from therapeutic referencing or the pharmacoeconomic price. Moreover, in a case study of 7 medicines granted

Presently, Cost-Effectiveness Analysis has been increasingly adopted in health technology assessment. In addition, it is recognized as an important tool for policy makers in the health care resource allocation decision making process. However, the presentation of Cost-Effectiveness Analysis results in terms of cost per Quality-Adjusted Life Year (Q

If we raise the word “addiction” to you, what are the things you are thinking of? Ecstasy? Methamphetamine? Cannabis? That is true. Addiction normally refers to drug addiction or substances that we take into our body and cause desire to retake it again. Addiction also harms both physical and mental

Sitaporn Youngkong MSc, PhD* * Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand This article provides an overview of the potential uses of health technology assessment (HTA) in health technology or health intervention-related policy decision-

Apirujee Punjataewakupt, PhD, earned her doctoral degree in pharmaceutical sciences from Chulalongkorn University. She has diverse experience in both the pharmaceutical industry and health-related research. She is currently serving as a research assistant at the Health Intervention and Technology Assessment Program (HITAP).Her expertise includes ph

EXECUTIVE SUMMARY This annual report has been prepared to compile and summarise the activities of the Health Intervention and Technology Assessment Program (HITAP) projects in the past year (2023). It highlights various initiatives aligned with HITAP’s vision, mission, and strategic pillars, guid

EXECUTIVE SUMMARY This annual report has been prepared to compile and summarise the activities of the Health Intervention and Technology Assessment Program (HITAP) projects in the past year (2023). It highlights various initiatives aligned with HITAP’s vision, mission, and strategic pillars, guid

Angela is an International Cooperation Officer at the Health Intervention and Technology Assessment Program Foundation (HITAP), where she supports global partnerships and coordination of regional networks and platforms such as HTAsiaLink, SAPPHIRE, and GEAR. With a strong interest in bridging technical research and policy, she also contributes to r